TerrAscend: Analyst Consensus Estimates For Q3 2021

TerrAscend Corp (CSE: TER) announced that they will be reporting their third quarter financials before the markets open on November 16th.

Analysts have a consensus C$17.96 12-month price target on the company, via a total of 8 analysts, with 3 analysts having strong buy ratings, and the other 5 having buy ratings on the company. The street high comes from Stifel-GMP with an C$23 price target, and the lowest target comes from Needham & Company with a C$13.70 price target.

8 analysts have revenue estimates for the third quarter. The mean between all 8 is US$57.82 million; this number has been revised down from US$80.98 million at the start of May. The street high is US$62 million while the lowest sits at US$54.30 million.

7 analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 57.84%, with this number being lower than at the start of May. Street high is 60.70% estimate and the lowest sits at 52%.

Onto EBITDA estimates, there are currently 8 analysts who have third quarter EBITDA estimates. The mean is currently US$19.98 million, with this number has been revised downwards from US$34.01 million at the start of May. Street high sits at US$23.40 million EBITDA and the lowest being a US$15.90 million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why $100 Silver Right Now Would Be a Problem | Keith Neumeyer – First Majestic

Why Industrial Demand Is Changing the Silver Market | David Morgan

Gold and Silver Delivery Is Exposing the Paper Market | Andy Schectman

Recommended

Nations Royalty Names Derrick Pattenden As President And CEO

First Phosphate Receives US$530,000 Pre-Payment Under Offtake Agreement

Related News

Cronos Group: Canaccord, PI Reiterate Ratings, Adjust Revenue Estimates

Cronos Group (TSX: CRON) (NASDAQ: CRON) reported its second quarter financials on August 6 pre-market,...

Sunday, August 9, 2020, 04:20:00 PM

Medipharm Labs Receives Price Target Reduction From Canaccord To $1.75

Yesterday, On November 16th, Medipharm Labs (TSX: LABS) reported their third quarter financial results. Reported...

Tuesday, November 17, 2020, 03:37:00 PM

Antibe Therapeutics: Canaccord Initiates Coverage, Issues $1.50 Price Target

Recently, Canaccord Genuity’s Tania Gonsalves initiated coverage on Antibe Therapeutics (TSXV: ATE), a biotechnology company...

Tuesday, August 18, 2020, 01:46:28 PM

Kinross Gold: BMO Expects The Sale of Russian Assets

Last week, Kinross Gold Corporation (TSX: K) announced the suspension of its Russian operations. Impacted...

Sunday, March 13, 2022, 11:17:00 AM

BMO Cuts IAMGOLD’s Price Target On Rosebel Mine Divesture

IAMGOLD (TSX: IMG) announced yesterday that it has reached an agreement to sell its 95%...

Wednesday, October 19, 2022, 03:03:00 PM